gnbt fact sheet generex biotechnology corporation . investor fact sheet at a glance : symbol nasdaqsc : gnbt price ( 3 / 4 / 05 ) : $ 0 . 61 52 - week high / low : $ 0 . 58 / $ 1 . 86 av . volume ( 3 - mo ) : 303 , 681 shares outstanding : 34 . 76 million float : 29 . 6 million % held by insiders : 14 . 83 % market capitalization : $ 21 . 20 million cash : * $ 1 . 76 million long - tem debt : * $ 935 , 000 revenue * * $ 710 , 000 * as of 10 / 31 / 04 * * 12 months ended 10 / 31 / 04 insulin without pain , ready for market - - generex biotechnology ( nasdaqsc : gnbt ) has developed oral - lyn  , an oral insulin spray for the treatment of diabetes , thereby replacing insulin injections . - - after 10 years of development , oral - lyn  has been found to be as effective as injected insulin and is ready for commercialization . - - sales could start as early as the first half of 2005 in south america . canada and europe is the next target market , with u . s . and europe to follow . - - diabetes is growing at epidemic rates . hundreds of millions suffer from type 1 , type 2 or pre - diabetes . even modest penetration of the worldwide diabetes market would translate into revenues in the billion - dollar range . - - generex  s delivery system , rapidmist  , has the potential to replace injected drugs , including morphine , fentanyl , heparin and flu vaccine . why buy now generex biotechnology is a toronto - based , delaware corporation with a market - ready solution to a central challenge in diabetes treatment  ending the pain and hassle of insulin injections . ever since scientists early in the 20 th century learned that diabetes was caused by the body  s inability to produce a normal supply of insulin , patients have had to administer insulin by injection . alternatives that have been developed in recent years  pumps or needle - less  pens   are still invasive and / or expensive . pharmaceutical companies have tried to develop a truly non - invasive insulin product that is pain - free , easy to use and free from serious side effects . among today  s competing technologies , only oral - lyn  , an insulin spray to treatment diabetes , meets all those tests . after 10 years of development , oral - lyn  is ready for market and is set to produce enormous revenue growth for the company . generex is little known outside a small community of investors focused on drug delivery and diabetes treatment . in the next few months , however , the expected commercial entry of oral - lyn  in south america could raise generex  s profile sharply , with a commensurate rise in their share price . small companies in drug and medical - device development are , of course , inherently high - risk investments . but aggressive investors who take an early stake in these firms can profit several times over . generex has the profile of being one such potential winner . readers are advised that this investor fact sheet is intended for informational use only . anyone interested in obtaining more detailed information about the company should contact generex biotechnology ( generex ) or investor relations international ( iri ) . this investment profile was developed as part of an overall investor relations program with iri . iri has been retained by generex to provide investor relations advisory services , for which iri receives compensation in the form of cash . this investment fact sheet is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the company ' s stock . this investment fact sheet is based upon information available to the public , as well as other information from sources deemed reliable , but is not guaranteed as being accurate nor does it purport to be complete . this investment fact sheet may contain forward - looking statements within the meaning of section 27 a of the securities act of 1933 , as amended , and section 21 e of the securities exchange act of 1934 , as amended . these forward - looking statements are subject to a variety of risks and uncertainties , many of which are beyond generex  s control , which could cause actual results to differ materially from those contemplated in these forward - looking statements . existing and prospective investors are cautioned not to place undue reliance on these forward - looking statements , which speak only as of the date hereof . for additional information regarding these and other risks faced by the company , visit the company  s website at www . generex . com . this message is sent to you in compliance with the federal can - spam bill and the electronic commerce ( ec directive ) regulations of 2004 . this is a commercial email which includes an unsubscribe method for remove processing as mandated by law . footer also includes the sender ' s information . bizcap . info p . o . box 155 sugarloaf , ny . 10981 to be excluded from future mailings , please reply to this email with rem in the subject line .